Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease
© 2023. BioMed Central Ltd., part of Springer Nature..
BACKGROUND: Insulin resistance (IR) is a pathophysiologic hallmark of type 2 diabetes and associated with the presence of chronic kidney disease (CKD). Experimental studies suggest that endothelin-1 increases IR. We assessed the association between IR and cardio-renal outcomes and the effect of the selective endothelin receptor antagonist atrasentan on IR in patients with type 2 diabetes and CKD.
METHODS: We used data from the RADAR and SONAR trials that recruited participants with type 2 diabetes and CKD [eGFR 25-75 mL/min/1.73 m², urine albumin-to-creatinine ratio of 300-5000 mg/g]. IR was calculated using the homeostatic model assessment (HOMA-IR). The association between HOMA-IR and the pre-specified cardio-renal outcomes was assessed using multivariable Cox proportional hazards regression, and effects of atrasentan on HOMA-IR by a linear mixed effect model.
RESULTS: In the SONAR trial, each log-unit increase in HOMA-IR was associated with an increased risk of the composite cardio-renal outcome [hazard ratio 1.32 (95%CI 1.09,1.60; p = 0.004)], kidney outcome [hazard ratio 1.30 (95%CI 1.00,1.68; p-value = 0.048)], and the kidney or all-cause mortality outcome [hazard ratio 1.25 (95%CI 1.01,1.55; p-value = 0.037)]. After 12 weeks treatment in the RADAR trial (N = 123), atrasentan 0.75 mg/day and 1.25 mg/day compared to placebo reduced HOMA-IR by 19.1 (95%CI -17.4, 44.3) and 26.7% (95%CI -6.4, 49.5), respectively. In the SONAR trial (N = 1914), atrasentan 0.75 mg/day compared to placebo reduced HOMA-IR by 9.6% (95%CI 0.6, 17.9).
CONCLUSIONS: More severe IR is associated with increased risk of cardio-renal outcomes. The endothelin receptor antagonist atrasentan reduced IR.
TRIAL REGISTRATION: RADAR trial (Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With AtRasentan): NCT01356849. SONAR trial (The Study Of Diabetic Nephropathy With AtRasentan) NCT01858532.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
---|---|
Enthalten in: |
Cardiovascular diabetology - 22(2023), 1 vom: 16. Sept., Seite 251 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Smeijer, J David [VerfasserIn] |
---|
Links: |
---|
Themen: |
Atrasentan |
---|
Anmerkungen: |
Date Completed 18.09.2023 Date Revised 21.11.2023 published: Electronic ClinicalTrials.gov: NCT01858532, NCT01356849 Citation Status MEDLINE |
---|
doi: |
10.1186/s12933-023-01964-8 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM362140421 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM362140421 | ||
003 | DE-627 | ||
005 | 20231226090625.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12933-023-01964-8 |2 doi | |
028 | 5 | 2 | |a pubmed24n1207.xml |
035 | |a (DE-627)NLM362140421 | ||
035 | |a (NLM)37716952 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Smeijer, J David |e verfasserin |4 aut | |
245 | 1 | 0 | |a Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.09.2023 | ||
500 | |a Date Revised 21.11.2023 | ||
500 | |a published: Electronic | ||
500 | |a ClinicalTrials.gov: NCT01858532, NCT01356849 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. BioMed Central Ltd., part of Springer Nature. | ||
520 | |a BACKGROUND: Insulin resistance (IR) is a pathophysiologic hallmark of type 2 diabetes and associated with the presence of chronic kidney disease (CKD). Experimental studies suggest that endothelin-1 increases IR. We assessed the association between IR and cardio-renal outcomes and the effect of the selective endothelin receptor antagonist atrasentan on IR in patients with type 2 diabetes and CKD | ||
520 | |a METHODS: We used data from the RADAR and SONAR trials that recruited participants with type 2 diabetes and CKD [eGFR 25-75 mL/min/1.73 m², urine albumin-to-creatinine ratio of 300-5000 mg/g]. IR was calculated using the homeostatic model assessment (HOMA-IR). The association between HOMA-IR and the pre-specified cardio-renal outcomes was assessed using multivariable Cox proportional hazards regression, and effects of atrasentan on HOMA-IR by a linear mixed effect model | ||
520 | |a RESULTS: In the SONAR trial, each log-unit increase in HOMA-IR was associated with an increased risk of the composite cardio-renal outcome [hazard ratio 1.32 (95%CI 1.09,1.60; p = 0.004)], kidney outcome [hazard ratio 1.30 (95%CI 1.00,1.68; p-value = 0.048)], and the kidney or all-cause mortality outcome [hazard ratio 1.25 (95%CI 1.01,1.55; p-value = 0.037)]. After 12 weeks treatment in the RADAR trial (N = 123), atrasentan 0.75 mg/day and 1.25 mg/day compared to placebo reduced HOMA-IR by 19.1 (95%CI -17.4, 44.3) and 26.7% (95%CI -6.4, 49.5), respectively. In the SONAR trial (N = 1914), atrasentan 0.75 mg/day compared to placebo reduced HOMA-IR by 9.6% (95%CI 0.6, 17.9) | ||
520 | |a CONCLUSIONS: More severe IR is associated with increased risk of cardio-renal outcomes. The endothelin receptor antagonist atrasentan reduced IR | ||
520 | |a TRIAL REGISTRATION: RADAR trial (Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With AtRasentan): NCT01356849. SONAR trial (The Study Of Diabetic Nephropathy With AtRasentan) NCT01858532 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Atrasentan | |
650 | 4 | |a Chronic kidney disease | |
650 | 4 | |a Endothelin receptor antagonist | |
650 | 4 | |a Insulin resistance | |
650 | 4 | |a Type 2 diabetes | |
650 | 7 | |a Atrasentan |2 NLM | |
650 | 7 | |a V6D7VK2215 |2 NLM | |
650 | 7 | |a Endothelin Receptor Antagonists |2 NLM | |
700 | 1 | |a Kohan, Donald E |e verfasserin |4 aut | |
700 | 1 | |a Rossing, Peter |e verfasserin |4 aut | |
700 | 1 | |a Correa-Rotter, Ricardo |e verfasserin |4 aut | |
700 | 1 | |a Liew, Adrian |e verfasserin |4 aut | |
700 | 1 | |a Tang, Sydney C W |e verfasserin |4 aut | |
700 | 1 | |a de Zeeuw, Dick |e verfasserin |4 aut | |
700 | 1 | |a Gansevoort, Ron T |e verfasserin |4 aut | |
700 | 1 | |a Ju, Wenjun |e verfasserin |4 aut | |
700 | 1 | |a Lambers Heerspink, Hiddo J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cardiovascular diabetology |d 2002 |g 22(2023), 1 vom: 16. Sept., Seite 251 |w (DE-627)NLM119878380 |x 1475-2840 |7 nnns |
773 | 1 | 8 | |g volume:22 |g year:2023 |g number:1 |g day:16 |g month:09 |g pages:251 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12933-023-01964-8 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 22 |j 2023 |e 1 |b 16 |c 09 |h 251 |